| Catalog Number |
PR60607343 |
| CAS |
60607-34-3 |
| Description |
Oxatomide is a member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug. It has a role as a geroprotector, a H1-receptor antagonist, an anti-allergic agent, an anti-inflammatory agent and a serotonergic antagonist. |
| Synonyms |
Tinset; Celtect; Cobiona; Dasten |
| IUPAC Name |
3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one |
| Molecular Weight |
426.6 |
| Molecular Formula |
C27H30N4O |
| InChI |
BAINIUMDFURPJM-UHFFFAOYSA-N |
| InChI Key |
InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32) |
| Documentation/Certification |
CEP |
| Drug Categories |
Anti-Allergic Agents; Anti-Asthmatic Agents; Antihistamines for Systemic Use; Histamine Agents; Histamine Antagonists; Histamine H1 Antagonists; Moderate Risk QTc-Prolonging Agents; Neurotransmitter Agents; Piperazine Derivatives; QTc Prolonging Agents; Respiratory System Agents |
| Drug Interactions |
Acrivastine-The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Oxatomide.
Adenosine-The risk or severity of QTc prolongation can be increased when Adenosine is combined with Oxatomide.
Ajmaline-The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Oxatomide.
Albuterol-The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Oxatomide.
Alfuzosin-The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Oxatomide. |
| Isomeric SMILES |
C1CN(CCN1CCCN2C3=CC=CC=C3NC2=O)C(C4=CC=CC=C4)C5=CC=CC=C5 |
| Type |
Small Molecule |
It should be noted that our service is only used for research, not for clinical use.
